Glycaemic efficacy and safety of ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from VERTIS CV

被引：0
|
作者：
Dagogo-Jack, S. [1 ]
Pratley, R. E. [2 ]
Cherney, D. Z. I. [3 ]
Charbonnel, B. [4 ]
McGuire, D. K. [5 ,6 ]
Cosentino, F. [7 ,8 ]
Shih, W. J. [9 ,10 ]
Liu, J. [11 ]
Frederich, R. [12 ]
Mancuso, J. P. [13 ]
Raji, A. [11 ]
Gantz, I. [11 ]
机构：
[1] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA
[2] AdventHlth Translat Res Inst, Orlando, FL USA
[3] Univ Toronto, Toronto, ON, Canada
[4] Univ Nantes, Nantes, France
[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[6] Parkland Hlth & Hosp Syst, Dallas, TX USA
[7] Karolinska Inst, Unit Cardiol, Stockholm, Sweden
[8] Karolinska Univ Hosp, Stockholm, Sweden
[9] Rutgers Sch Publ Hlth, Piscataway, NJ USA
[10] Rutgers Canc Inst New Jersey, Piscataway, NJ USA
[11] Merck & Co Inc, Kenilworth, NJ USA
[12] Pfizer Inc, Collegeville, PA USA
[13] Pfizer Inc, Groton, CT 06340 USA
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
438
引用
收藏
页码：225 / 226
页数：2
相关论文
共 50 条
  • [1] Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial
    Dagogo-Jack, Samuel
    Pratley, Richard E.
    Cherney, David Z., I
    McGuire, Darren K.
    Cosentino, Francesco
    Shih, Weichung J.
    Liu, Jie
    Frederich, Robert
    Mancuso, James P.
    Raji, Annaswamy
    Gantz, Ira
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [2] Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV
    Dagogo-Jack, Samuel
    Pratley, Richard E.
    Cherney, David
    Charbonnel, Bernard
    Mcguire, Darren K.
    Cosentino, Francesco
    Shih, Weichung J.
    Liu, Jie
    Frederich, Robert
    Mancuso, James P.
    Raji, Annaswamy
    Gantz, Ira
    [J]. DIABETES, 2021, 70
  • [3] Ertugliflozin in older patients with type 2 diabetes: an analysis from VERTIS CV
    Pratley, R. E.
    Cannon, C. P.
    Charbonnel, B.
    Cherney, D. Z. I.
    Cosentino, F.
    McGuire, D. K.
    Shih, W. J.
    Essex, M. N.
    Lawrence, D.
    Jones, P. L. S.
    Liu, J.
    Adamsons, I. A.
    Dagogo-Jack, S.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 30 - 31
  • [4] Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
    Grunberger, George
    Camp, Sarah
    Johnson, Jeremy
    Huyck, Susan
    Terra, Steven G.
    Mancuso, James P.
    Jiang, Zhi Wei
    Golm, Gregory
    Engel, Samuel S.
    Lauring, Brett
    [J]. DIABETES THERAPY, 2018, 9 (01) : 49 - 66
  • [5] Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
    George Grunberger
    Sarah Camp
    Jeremy Johnson
    Susan Huyck
    Steven G. Terra
    James P. Mancuso
    Zhi Wei Jiang
    Gregory Golm
    Samuel S. Engel
    Brett Lauring
    [J]. Diabetes Therapy, 2018, 9 : 49 - 66
  • [6] Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy
    Lingvay, Ildiko
    Greenberg, Michelle
    Gallo, Silvina
    Shi, Harry
    Liu, Jie
    Gantz, Ira
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (07): : 1640 - 1651
  • [7] Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV
    Pratley, Richard E.
    Dagogo-Jack, Samuel
    Charbonnel, Bernard
    Cherney, David
    Cosentino, Francesco
    Mcguire, Darren K.
    Essex, Margaret N.
    Jones, Philip L. S.
    Liu, Jie
    Adamsons, Ingrid A.
    Lawrence, David
    Shih, Weichung J.
    Cannon, Christopher P.
    [J]. DIABETES, 2021, 70
  • [8] Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV
    Cherney, D. Z. I.
    Segar, M.
    Pandey, A.
    Cannon, C. P.
    Cosentino, F.
    Dagogo-Jack, S.
    Pratley, R. E.
    Frederich, R.
    Cater, N. B.
    Maldonado, M.
    Liu, J.
    Liu, C. -C.
    Pong, A.
    McGuire, D. K.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2925 - 2925
  • [9] Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
    Budoff, Matthew J.
    Davis, Timothy M. E.
    Palmer, Alexandra G.
    Frederich, Robert
    Lawrence, David E.
    Liu, Jie
    Gantz, Ira
    Derosa, Giuseppe
    [J]. DIABETES THERAPY, 2021, 12 (05) : 1279 - 1297
  • [10] Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
    Matthew J. Budoff
    Timothy M. E. Davis
    Alexandra G. Palmer
    Robert Frederich
    David E. Lawrence
    Jie Liu
    Ira Gantz
    Giuseppe Derosa
    [J]. Diabetes Therapy, 2021, 12 : 1279 - 1297
12345